A new lateral flow test (Cozart RapiScan System) detects MDMA and methamphetamine in oral fluid with high accuracy. Among 370 oral fluid samples, 121 screened positive. Using a 45 ng/mL screening cutoff and 30 ng/mL confirmation cutoff, sensitivity was 96.6%, specificity 96.8%, and accuracy 96.8%. The test also cross-reacts with high levels of amphetamine, causing six false positives. Applying a 50 ng/mL confirmation cutoff improved sensitivity to 98.3%, specificity to 96.9%, and accuracy to 97.3%. Confirmatory testing by gas chromatography-mass spectrometry identified multiple amphetamines.
A new microplate enzyme immunoassay (EIA) detects lysergic acid diethylamide (LSD) in human urine by having LSD in the sample compete with immobilized LSD for binding to rabbit anti-LSD antibodies. The assay requires only 25 microliters of urine and three incubation periods at room temperature. It showed no cross-reaction with other drugs, including ergot alkaloids at up to 100,000 ng/mL, and only slight cross-reactivity with ergonovine (0.0008%). Nor-LSD cross-reacted between 16% and 28%. At a qualitative cutoff of 0.5 ng/mL, precision testing gave a coefficient of variation of 6%.